MYDECINE™

MEDICINE EVOLVED

June 2022

Mydecine Innovations Group

NEO : MYCO
OTC : MYCOF
FSE : 0NFA

Disclaimer

General

The information provided in this presentation pertaining to Mydecine Innovations Group Inc. (“Mydecine" or the "Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, Mydecine and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Mydecine expressly disclaims any and all liability that may be based on such information or errors or omissions thereof.

Mydecine reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof. The information contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of evaluating the Company. The information contained in this presentation supersedes any prior presentation or conversation concerning the Company. Any information, representations or statements not contained herein shall not be relied upon for any purpose. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by third parties in respect of the matters discussed in this presentation.

Confidentiality

This presentation is confidential and is intended, among other things, to present a general outline of the Company. The contents are not to be reproduced or distributed to the public or press. Each person who has received a copy of this presentation (whether or not such person purchases any securities) is deemed to have agreed: (i) not to reproduce or distribute this presentation, in whole or in part, without the prior written consent of the Company, other than to legal, tax, financial and other advisors on a need to know basis, (ii) if such person has not purchased securities, to return this presentation to the Company upon its request (iii) without the prior written consent of the Company, not to disclose any information contained in this presentation except to the extent that such information was (a) previously known by such person through a source (other than the Company) not bound by any obligation to keep such information confidential, (b) in the public domain through no fault of such person, or (c) lawfully obtained at a later date by such person from sources (other than the Company) not bound by any obligation to keep such information confidential, and (iv) to be responsible for any disclosure of this presentation, or the information contained herein, by such person or any of its employees, agents or representatives.

Forward-Looking Statements

Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and “financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

About Mydecine

Mydecine is a biotechnology company developing innovative first- and second-generation novel therapeutics to treat mental health and addiction disorders. Our team has extensive experience in drug development, medicinal chemistry, clinical trials, mental health and addiction disorders.





Executive Summary

Global Partnerships

- Exclusive partnership with Applied Pharmaceutical Innovations working out of the University of Alberta
- Strategic partners with leading psychedelic research center Johns Hopkins University
- Strong relationships with academic organizations advancing psychedelic research

IP and Drug Development

- Global team with extensive experience in medicinal chemistry, pharmaceutical drug development, regulatory and IP strategy
- Developing novel molecules tailored for medical use with improved efficacy, controllability, delivery mechanisms and safety
- Layered approach to patent strategy maximizing protection and increasing value
- Utilizing advanced artificial intelligence and machine learning to design and screen drugs of interest

Clinical Trials

- Only industry sponsored clinical trial assessing psilocybin-assisted therapy as a smoking cessation treatment
- Providing lead drug candidate MYCO-001 for two smoking cessation studies in 2022
- Working closely with internationally recognized consulting firms ProPharma Group and Ethica CRO

Our Mission & Vision

Mission

Our mission is to become a trusted source of safe and effective medication-based treatments to address the unmet needs for mental health and addiction disorders.

Vision

Through technology and research, our vision is to become the number one globally trusted leader in the treatment of mental health and addiction disorders. We see success when all medical and therapy communities view psychedelic medicine as an accepted and adopted form of treatment offered in our existing healthcare infrastructure.

MYDECINE™
MEDICINE EVOLVED

Our Approach

IP & Drug Development

Clinical Trials

IP & Drug Development



MYDECINE™
MEDICINE EVOLVED

R&D Team

Meet our team of highly experienced chemists, doctors and scientists specialized in pharmaceutical chemistry, natural products chemistry and drug development:

Robert Roscow, M.A.

Chief Scientific Officer
Mydecine Innovations Group
Expertise: genetics, drug development, pharmaceutical R&D, complex chemistry

Andrew MacIsaac

CEO
Applied Pharmaceutical Innovation
Expertise: Leadership, drug development strategy & economics, interdisciplinary bridge builder to bring drugs from research to patient's bedside

Dr. Khaled H. Barakat, Ph.D., M.S., EIT

Principal Investigator (UAlberta)
Applied Pharmaceutical Innovation
Expertise: Artificial intelligence and machine learning drug development, physics and biology

Dr. Raimar Loebenberg, B.S., Ph.D.

Director, Drug Development (UAlberta)
Applied Pharmaceutical Innovation
Expertise: pharmaceutics, drug development, delivery systems, formulation, GMP manufacturing

Dr. Vijay Somayaji, B.S., Ph.D.

Manager, DDIC & Head of QA/QC
Applied Pharmaceutical Innovation
Expertise: chemistry, biotech, product development, quality assurance and quality control

Dr. Brian Duff Sloley, B.S., M.S., Ph.D.

Senior Scientist
Applied Pharmaceutical Innovation
Expertise: comparative neurobiology, neurotransmitter identification, botanical composition

R&D Team

Meet our team of highly experienced chemists, doctors and scientists specialized in pharmaceutical chemistry, natural products chemistry and drug development:

Allan Aginsky

Vice President, Production & Special Projects
Applied Pharmaceutical Innovation
Expertise: pharmaceutical development and implementation of drug manufacturing projects

Dr. Chuanjun (CJ) Gao, B.S., M.S., Ph.D.

Chemist
Applied Pharmaceutical Innovation
Expertise: complex chemistry, multi-step syntheses, novel compound development

Vladimir Khlebnikov

Chemist
Applied Pharmaceutical Innovation
Expertise: pharmaceutical R&D, complex chemistry

Archana Koul, B.S., M.S., Ph.D.

Research Scientist
Applied Pharmaceutical Innovation
Expertise: Molecular biology, plant genomics, toxicology, analytical method development

Dr. Rong Ling

Chemist
Applied Pharmaceutical Innovation
Expertise: pharmaceutical R&D, complex chemistry

Lead Drug Candidates

MYDECINE™
MEDICINE EVOLVED

Product Candidate	Potential Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
001 MYCO - 001 99% pure psilocybin	Smoking Cessation					
004 MYCO - 004 Patch-delivered tryptamine compound	Smoking Cessation TBD					
005 MYCO - 005 psilocybin analogs (heart safe microdose)	TBD (ideal for longterm use)					
006 MYCO - 006 short-acting MDMA analogs	Anxiolytic					

Lead Drug Candidates

MYCO - 004

Patch-delivered tryptamine compound

- Unique fast track approval
- Skin permeable and patch delivered
- Two-hour duration
- Faster onset time
- Reduced side effects
- Multiple layers of patent protection
- Better suited for existing healthcare infrastructure

MYCO - 005

Family of improved psilocin analogs

- Increased safety and stability profile
- Strong binding at 5-HT2A receptor
- Non-binding at 5-HT2B receptor (potentially heart safe)
- Faster onset time
- Strong potential to pair with skin permeable feature set

MYCO - 006

Family of short-acting MDMA analogs

- Increased safety and stability profile
- 1-2 hour duration
- More scalable treatment with shorter half-life
- Reduced cost of treatment by decreasing total treatment time
- Better suited for existing healthcare infrastructure

Artificial Intelligence Drug Discovery Program

- Through our exclusive partnership with Applied Pharmaceutical Innovation and the University of Alberta, we are utilizing artificial intelligence and machine learning (AI/ML) to design and screen our drugs of interest
- The University of Alberta is ranked top 3 globally for AI research and considered Canada's #1 Computing Science Department
- Our program is led by top computer-aided drug development expert, Dr. Khaled Barakat, in conjunction with researchers at the University of Alberta
- Through AI/ML we are able to screen billions of compounds rapidly without the need to produce them and immediately collect data on viable drug candidates prior to further investment in development
- Our program combines AI with in-silico structural modeling to design novel serotonin receptor modulators and assess drugs around these receptors
- We have completed a target-based model of the classic psychedelic serotonin receptors 5-HT2A, 5-HT2B, and will continue to build receptor models to include the complete family of serotonin receptors

https://www.ualberta.ca/research/our-research/key-strengths/ai.html

Clinical Trials

MYDECINE™
MEDICINE EVOLVED

Clinical Trial Highlights

Johns Hopkins University is the lead investigator for two concurrently running MYCO-001 smoking cessation studies launching in 2022

Mydecine is the only biotech company targeting smoking cessation as an indication

Our industry sponsored smoking cessation study builds off Dr. Matthew Johnson's ongoing research showing an 80% efficacy rate at six months

Addiction Crisis and Growing Market Opportunity

- In the U.S., tobacco kills more than AIDS, alcohol, car accidents, illegal drugs, murders and suicides combined
- 68% of smokers would like to quit but only 7.5% are successful
- $64 billion increase in global smoking cessation market by 2026
- $1.1 billion opportunity after Chantix recall in 2021

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#:~:text=Cigarette%20smoking%20is%20responsible%20for,or%201%2C300%20deaths%20every%20day.&text=On%20average%2C%20smokers%20die%2010%20years%20earlier%20than%20nonsmokers.

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
https://www.tobaccofreekids.org/problem/toll-us

https://www.businesswire.com/news/home/20200319005381/en/Global-Smoking-Cessation-Market---Expected-to-Reach-63.99-Billion-by-2026-Growing-at-a-CAGR-of-16.9---ResearchAndMarkets.com

https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix

https://www.fiercepharma.com/pharma/endo-s-smoking-cessation-generic-rushed-over-fda-s-finish-line-effort-to-fill-chantix

MYDECINE™ MEDICINE EVOLVED

Positive Clinical Data Assessing Psilocybin for Smoking Cessation

JOHNS HOPKINS UNIVERSITY

Lead Researcher
Dr. Matthew Johnson, Ph.D.

2016 Smoking Cessation Study

- 15 participants
- Psilocybin + cognitive behavioral therapy (CBT) (3 doses)
- 12 month follow-up
- 67% abstinence from smoking

2022 Smoking Cessation Study

- 100 participants
- Psilocybin + cognitive behavioral therapy (CBT) (1 dose)
  Nicotine Replacement Therapy + CBT
- 12 month follow-up
- 59% abstinence from smoking
  28% abstinence from smoking

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641975/#R1

MYCO-001 Smoking Cessation Studies

JOHNS HOPKINS UNIVERSITY

Lead Researcher

Dr. Matthew Johnson, Ph.D.

Industry Sponsored Phase 2b Clinical Trial

- 1st industry sponsored trial assessing psilocybin for smoking cessation
- Lead Investigator Johns Hopkins University
- Anticipated IND Approval Q4 2022
- MYCO-001 (single dose) + CBT vs placebo

Investigator Initiated NIH Grant-Funded Clinical Trial

- 1st time in 50 years that the US Federal Government has funded the study of psychedelics for therapeutic use
- Johns Hopkins University, New York University, University of Alabama Birmingham
- IND approved in Q2 2022
- MYCO-001 (2 doses) + CBT vs placebo

*National Institutes of Health (NIH)

MYCO-001 - for Smoking Cessation

Candidate: MYCO-001, 99% pure psilocybin

Indication: Smoking Cessation

TWO CLINICAL TRIALS

1. Industry Sponsored Phase 2b Clinical Trial

2. Investigator Initiated NIH Grant-Funded Study

Research: Led by Dr. Matthew Johnson, Ph.D.

Q1 2022 / Q2 2022	Q3 2022	Q4 2022	Q1 2023
• Conditional IRB approval for Phase 2b study • IND Approved for NIH Study	• Anticipated patient recruitment for NIH study	• Anticipated IND Submission for Phase 2b Study • Anticipated approval of IND for Phase 2b study	• Anticipated patient recruitment for Phase 2b study

MYCO-004 - for Smoking Cessation

Candidate: MYCO-004, tryptamine compound patch-delivered

Indication: Substance Use Disorder, Smoking Cessation, TBD

Preclinical / IND-enabling studies

Research: To Be Announced

Q4 2021	Q2 2022	Q4 2022
• Filed MCYO-004 final patent application		• Preclinical/nonclinical studies

Programs, Partnerships and Leadership Team

MYDECINE™
MEDICINE EVOLVED

Global Partnerships

UNIVERSITY OF ALBERTA

api APPLIED PHARMACEUTICAL INNOVATION

- Through our exclusive partnership with API, we have access to a world-class, end-to-end drug development infrastructure at the University of Alberta led by a highly experienced team all under one roof.
- University of Alberta's Faculty of Pharmacology is currently ranked in the top 15 in the world for pharmaceutical drug discovery. Their artificial intelligence program is ranked top 3 in the US and Canada.

JOHNS HOPKINS UNIVERSITY

- We have partnered with Johns Hopkins University (JHU) to advance our clinical trial and research initiatives.
- JHU is considered the top university for psychedelic research globally and will act as the the flagship site for two MYCO-001 smoking cessation studies launching in 2022.
- We have a 5-year master collaboration research agreement with JHU to research multiple molecules for a variety of indications.

ethica CRO

PROPHARMA GROUP®

- Through our partnerships with Ethica CRO and ProPharma Group, we have enhanced our protocols and clinical trial development while streamlining procedures to increase efficiencies and reduce risk.
- We have been working closely with these internationally recognized consulting firms to ensure all regulatory requirements are met or exceeded.

Sponsored Research

Sponsored psilocybin study led by Principal Investigator Dr. Jaylyn Waddell. Intriguing potential insight into the mechanism of psilocybin and provides a roadmap for biomarker discovery.

Microdosing study led by Principal Investigator Dr. David Erritzoe. Creation of a novel collaborative psychopharmacology/psychedelic research clinic between ICL and a major mental health NHS Trust in London.

Microdosing study led by Principal Investigator Dr. Vince Polito. This is the first study to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.

https://www.google.com/url?q=https://hub.jhu.edu/2019/09/04/hopkins-launches-psychedelic-center/&sa=D&source=docs&ust=1643330734983618&usg=AOvVaw0ASxK-bu1yapzq8Cv3M8tC

Special Access Support and Supply Program



- Healthcare providers can now apply for psilocybin and MDMA to treat qualified patients through Health Canada's Special Access Program (SAP)
- We have launched the Special Access Support and Supply Program (SASSP)
- Through our program we can offer support to clinics and physicians looking to treat patients with psilocybin and MDMA in Canada
- Our program aims to promote safe and effective therapy outcomes, create long-term relationships with hospitals, and expand patient access to treatments
- SASSP is a package of goods and services including cGMP psilocybin, training and advisory services, investigative brochures, protocols, and therapy manuals

Leadership Team

Joshua Bartch, Director, Chief Executive Officer

Mr. Bartch is an experienced entrepreneur. He co-founded AudioTranscriptionist.com and founded the Denver-based dispensary, Doctor's Orders, in 2009. He later founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Mr. Bartch co-founded Cannabase.io, the most significant and sophisticated legal cannabis wholesale platform in the United States. Mr. Bartch took successful exits from AudioTranscriptionist.com, Doctor’s Orders and Cannabase.io.

Dean Ditto, Chief Financial Officer

Mr. Ditto is a seasoned executive with experience helping small and mid-market companies develop and execute strategic plans, while ensuring the accounting, finance and administrative capabilities scale appropriately to support growth objectives. He has served in leadership roles for 20+ years in multiple industries including health sciences, heading initiatives to build finance function capabilities, improve profits and secure capital. He brings experience in SEC reporting, business analytics and systems, cash management, internal controls, risk management and building compliance functions for regulated companies. Mr. Ditto recently led a financial services business turnaround, improving profits by $15 million annually, as well as collaborating with operations to restructure a medical device business unit, increasing profits by $10 million annually.

Robert Roscow, Director, Chief Scientific Officer

As an experienced geneticist, Mr. Roscow has spent his academic and professional career identifying valuable and unique medicinal molecules found in nature. He holds both master’s and bachelor’s degrees in biology. Prior to joining Mydecine, Mr. Roscow was director of genetics at Victory Hemp Foods and also at ebbu, which was acquired as a subsidiary of Canopy Growth Corporation, the largest cannabis company in the world. At ebbu, Mr. Roscow ran the world’s first cannabis genetic editing laboratory. He has leveraged an expertise in genomics, evolution and molecular biology to identify novel molecules and advance their use in a pharmacological context. His work has resulted in multiple patent filings and accolades in a variety of scientific and popular publications.

Damon Michaels, Director, Chief Operating Officer

Mr. Michaels previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as general manager for ebbu, a top multi-platform cannabinoid research and technology firm. By 2018, ebbu was the cutting-edge leader in cannabinoid science and was acquired for CAD$429 million by Canopy Growth Corporation, the largest cannabis company in the world. Mr. Michaels has held executive roles with multiple large brands throughout the cannabis vertical. He also served on the business development team for a Google Ventures company, developed a national snowboard brand and was one of four entrepreneurs who created Colorado’s first-ever glass recycling company.

Leadership Team

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, Chief Medical Officer

Dr. Jetly is the former chief of psychiatry for the Canadian Armed Forces and retired in 2021 as a colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon deploying on missions in Rwanda and the Middle East. He spent his final 20 years as a psychiatrist deploying twice and leading mental health programs in Afghanistan. Dr. Jetly maintains academic appointments at Dalhousie University and the University of Ottawa. He is the inaugural chair of the CF Brigadier Jonathan C. Meakins CBE, RCMAC, and chair in Military Mental Health at the Royal Ottawa Hospital. During his career, Dr. Jetly has led initiatives within Canada and NATO to better understand and innovate solutions in the mental health field. He has published extensively on topics such as PTSD, suicide, leveraging technology in mental health and occupational psychiatry.

Jessica R. Riggleman, Senior Director of Clinical & Regulatory Affairs

Ms. Riggleman has spent the past 10 years in the clinical research industry and has worked closely with cross-functional teams to develop clinical evidence generation strategies for global indication submissions. She has supported and published research in robotics, orthopedics, trauma, biologics, transcranial magnetic stimulation and psychedelic-assisted psychotherapy. Ms. Riggleman received her Masters of Science in Clinical Research Administration from George Washington University in Washington, D.C.

Sanford M. Stein, General Counsel

Mr. Stein is an experienced attorney and business advisor with expertise in all aspects of government-driven legal matters including legislation, regulations, lobbying and litigation. For more than 40 years, he has been counseling private sector clients and managing their relationships with government, and he brings to Mydecine vast business regulatory experience in the United States and internationally. Mr. Stein has been featured in Leading Lawyers, Super Lawyers and Best Lawyers in America, and he holds the coveted AV rating for professionalism and ethics by the Martindale-Hubbell rating service.

Questions?

MYDECINE™
MEDICINE EVOLVED

Investor Relations Contact

corp@mydecineinc.com
720-277-9879

USA Office
1250 S. Parker Rd.
Lower Level, Suites A
Denver, CO 80231

Canada Office
905 West Pender Street
6th Floor,
Vancouver BC V6C 1L6

@mydecineig @mydecine Mydecine Innovations Group